NDAINHALATIONSPRAY, METERED
Approved
Jul 2014
Lifecycle
LOE Approaching
Competitive Pressure
25/100
Data completeness
3/8 — Basic
Drug data last refreshed 8h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
STRIVERDI RESPIMAT is an inhaled metered-dose spray containing olodaterol, a long-acting beta-2 agonist (LABA) for maintenance treatment of chronic obstructive pulmonary disease (COPD). The drug works by activating beta-2 adrenergic receptors in airway smooth muscle, promoting bronchodilation and improving airflow. It is delivered via the proprietary Respimat soft-mist inhaler technology.
$5.0MPart D
LOE ApproachingDeclining
5mo to LOEWith LOE approaching in 2027 and modest Part D spending, the brand team is likely consolidating and shifting focus toward lifecycle extension or next-generation assets.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
Patent cliff in less than a year — expect lifecycle management and generic defense hiring
Worked on STRIVERDI RESPIMAT at Boehringer Ingelheim? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.